Objective. Atherogenic serum lipid profile possesses pro-inflammatory properties and is associated with more active RA. While prevalent in patients with gout, whether atherogenic lipid profile is associated with gouty flares is unknown. This study aims to investigate whether atherogenic serum lipid predicts gouty flares in patients with gout. Methods. Adult patients (age !21 yrs) who suffered from gout were prospectively followed between September 2006 and November 2007 and their demographic, clinical and laboratory data were collected. Episodes of gouty flares over this observation period were recorded and factors predictive of gouty flares were studied by regression models. Results. Of the 100 patients, 80 were men, 65 were ethnic Chinese, 31 were Malay and the rest were Indian and Caucasian. The mean age and duration of gout (AES.D.) were 61.9 AE 14.0 and 6.6 AE 7.8 yrs, respectively. The mean serum uric acid and creatinine levels were 537.6 AE 142.8 and 173.6 AE 119.9 mmol/l, respectively. In univariate analysis, longer duration of gout, higher adjusted mean serum creatinine, lower adjusted mean fasting serum, total cholesterol and high-density lipoprotein cholesterol (HDL-C) levels were associated with gouty flares. After adjustment for potential confounders in multivariate regression models, longer duration of gout and lower adjusted mean fasting serum HDL-C level remained independently predictive of gouty flares. Conclusions. Low serum high-density lipoprotein cholesterol level was an independent predictor for gouty flares. Whether optimizing serum HDL-C level can benefit patients with gout in terms of reducing gouty flares needs to be addressed by controlled trials.
Introduction
Gouty arthropathy is one of the commonest forms of crystalinduced arthropathy that affects 1-3% of the general population [1, 2] . While factors such as metabolic syndrome, high serum uric acid (UA) level, high seafood intake and low dairy and caffeine intake are associated with higher incidence of gout [3] [4] [5] , exploration of factors that precipitate gouty flares has not been equally robust. The as yet well-known triggering factors of gouty flares include non-compliance of urate-lowering agents (ULA), trauma, starvation, surgery, drugs that affect serum UA level and consumption of purine-rich food and beverages [6] [7] [8] [9] . Nevertheless, a proportion of patients who are not significantly burdened with these factors but carrying other comorbidities suffer from varying frequencies of gouty flares, leading to impaired health-related quality of life and dissatisfaction with health [8, 10] . This implies that other factors contributing to gouty flares need to be sought.
Dyslipidaemia or atherogenic lipid profile, one of the components of the metabolic syndrome, was shown to be associated with higher prevalence and incidence of gout [11, 12] . More recently, atherogenic lipid profile such as low serum high-density lipoprotein cholesterol (HDL-C) level was found to be associated with several inflammatory and autoimmune conditions, such as atherosclerosis [13] , RA [14] , Kawasaki's disease [15] and AS [16] . Patients with active RA were shown to have increased serum HDL and apolipoprotein A-1 (Apo-A1) levels compared with the pre-treatment levels after effective treatment for RA [17] . Furthermore, a recent study demonstrated that up to 10 yrs prior to the development of arthritis symptoms, patients who subsequently developed RA had lower averaged serum HDL-C level [18] . Taking these current data together, atherogenic lipid profile, especially low HDL-C level, may be associated with more active inflammation and arthritis. Since atherogenic lipid profile is prevalent in patients with gout, it is imperative to find out whether such unfavourable serum lipid profile contributes to precipitating gouty flares.
Patients and methods
Adult patients (age !21 yrs) who satisfied the 1977 ACR classification criteria for gout [19] were identified and prospectively followed between September 2006 and November 2007 in the Department of Medicine, National University Hospital, Singapore.
Patients with gout were evaluated at intervals between 4 and 16 weeks. The frequency of follow-up visits was based on the discretion of attending physicians according to their patients' clinical context. Demographic and clinical data including age, sex, race, age of gout onset, duration, family history and treatment of gout and comorbidities were collected through clinical interview and medical record review. Prospective laboratory parameters, such as serum UA and creatinine (Cr) levels, Cr clearance (CrCl), CRP and fasting lipid profiles that comprises total cholesterol (TC), HDL-C, low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG), were obtained from the computer database record system. The frequency of laboratory blood tests was based on the clinical contexts of the patients. The number of gouty flares over this 15-month observation period was ascertained from clinical interview. Gouty flare was defined as any rapid development of non-infective and transient arthritis or periarticular inflammation that necessitated the use of additional local or systemic anti-inflammatory agents including colchicine and corticosteroids [20] . Acute gouty flares which occurred within 2 months following initiation of ULA were not taken into account [21] . Since our patients were managed as per usual, short courses of colchicine and corticosteroids and adjustment of ULA dose were allowed during the observation period if they were indicated. This study was approved by the Institutional Review Board of our institution.
Statistical analyses
Unless otherwise specified, values are expressed as mean AE S.D. Simple descriptive statistics were used to describe demographic and clinical characteristics of our patients. Comparison of categorical data was made by the chi-square test and the Fisher's exact test was used instead when appropriate. Comparison of continuous data was made by using the Student's t-test and the one way analysis of variance where appropriate. Mann-Whitney U-test and Kruskal-Wallis test were used instead if the data did not follow a normal distribution or if equal variance could not be assumed. To ascertain valid estimations of outcomes with multiple observations, adjusted mean serum Cr, UA, CRP and fasting lipid levels used for analyses were derived by the area under the curve of the respective parameters over time by adding the areas of each respective block of visit intervals divided by the length of time for the whole period using the trapezium rule. The adjusted mean of these parameters is particularly suitable for this study because patients were evaluated at irregular intervals while the total duration of follow-up was similar in all patients. To minimize skewness, the frequency of gouty flares was log-transformed. Univariate linear analyses were performed to explore the relationships between frequency of gouty flares and various demographics and clinical parameters. Multiple linear regression models were constructed to identify factors predictive of gouty flares in our patients. To ascertain the validity of the multiple regression models, test of good fit and analyses of residuals were performed. Multicollinearities within the multiple regression models were detected by the tolerance test and a tolerance value >0.6 was accepted.
Statistical significance was defined as two-tailed P-value <0.05. All statistical analyses were performed by the SPSS program (Version 16.0 for Window Vista, Chicago, IL, USA).
Results
One hundred consecutive patients with gout were followed and their demographic and clinical data are summarized in Table 1 . Table 2 shows the results of the regression analyses. In univariate analysis, duration of gout, higher adjusted mean serum Cr level, lower adjusted mean fasting serum TC, lower adjusted mean HDL-C and LDL-C were significantly associated with frequency of gouty flares. In multiple linear regression, duration of gout and lower adjusted mean serum HDL-C level remained predictive of gouty flares after adjustment for age, gender, ethnicity, use of allopurinol and statins, and laboratory parameters comprising the serum CRP, UA, Cr, LDL-C and TG levels. Multicollinearities were detected in three pairs of covariates. They were (i) serum TC level and serum LDL-C level [Pearson coefficient (R) ¼ 0.926, P < 0.001], (ii) serum TC and serum HDL-C level (R ¼ 0.388, P < 0.001) and (iii) ischaemic heart disease and aspirin use (R ¼ 0.746, P < 0.001). To stabilize the regression model, aspirin use and serum TC level were excluded in the multivariate analyses (Table 2 ). In a second multivariate model that excluded ischaemic heart disease and serum LDL-C level while keeping aspirin use, serum TC level and the other covariates as in the original model, duration of gout (P ¼ 0.007) and serum HDL-C level (P ¼ 0.002) remained significantly associated with gouty flares.
Discussion
While higher prevalence and incidence of gout in individuals with atherogenic lipid profile have been well reported, our study demonstrates, for the first time, that low serum HDL-C level is a strong predictor of gouty flares.
Low serum HDL-C was shown to be associated with higher disease activity in a few inflammatory conditions [13] [14] [15] [16] [17] [18] 22] . In a case-control study, the change of serum HDL-C level was found to be inversely associated with that of the ESR in patients with RA and the HDL-C level increased after anti-inflammatory drug treatment [22] . In a prospective study of 42 treatment-naı¨ve patients with RA, effective control of disease activity was coupled with increments in serum HDL-C level and Apo-A1 by 21 and 23%, respectively, after disease-modifying treatment for 12 months [17] . Beyond demonstrating an association between atherogenic lipid and inflammatory arthritis, van Halm et al. [18] recently studied the lipid profile of stored blood samples from 1078 blood donors who donated blood between 1984 and 1999. It was found that the serum HDL-C level of the 79 donors who subsequently developed RA was on average 9% lower than that of the matched donors, even after adjusting for pro-inflammatory marker levels including the CRP [18] . This interesting yet important observation suggests that HDL-C might play a modulating role on inflammatory processes, as hypothesized by the authors of the study [18] . To substantiate this hypothesis, few laboratory studies demonstrated that Apo-A1 in HDL-C particles inhibits the interactions between inflammatory cells [23, 24] and suppresses IL-1-and TNF--driven pro-inflammatory reactions [24, 25] . Without doubt, further experiments with repeatable results are required to confirm the hypothetical link between low HDL-C and susceptibility of inflammation.
Although pathogenically distinct from RA, as alluded to above clinical observations and experiments, the putative mechanism by which HDL-C can protect against gouty flares can be postulated. During acute gout, upon recognition of the monosodium urate (MSU) crystals by the Toll-like receptors of the macrophages, the inflammasomes and subsequent downstream signalling pathways are activated. IL-1b, a pivotal cytokine involved in gouty inflammation, is then activated [26] [27] [28] . The activated IL-1b promotes endothelial cells inside the joint to express chemotactic factors that attract PMNs into the affected joints and periarticular structures [26] . The PMNs phagocytoze the MSU crystals and release inflammatory mediators in the vicinity, resulting in acute gout. In the abundance of HDL-C and Apo-A1 in the blood, this chain of reactions may be interrupted at the point where the expression of chemotactic factors on the endothelial cells is induced [26] . Consequential to this suppression, infiltration of PMNs is hampered and this mitigates subsequent gouty inflammation.
Although it can be argued that patients with gouty flares have a lower HDL-C level in the blood secondary to acute-phase response [29] , a few important steps pertaining to the design and statistical methods of this study were carefully implemented for minimizing this possibility. First, fasting lipid levels were essentially checked during follow-up visits when patients were flare free. Secondly, the adjusted mean serum lipid level was used as an independent variable in the regression model. Thirdly, we did a separate correlation analysis and found no significant relationship between the CRP level and any components in the lipid profiles. Finally, the adjusted mean CRP level was found to be uncorrelated with gouty flares, both in the univariate and multivariate analyses. With these precautions and findings, we conclude that the serum HDL-C was not substantially influenced by acute-phase response secondary to gouty flares in our patients.
Atherogenic lipid is prevalent in patients with gout and their lipid profiles should be optimized with the aim of reducing cardiovascular and cerebrovascular consequences. Based on the results of this study, tight control of serum HDL-C level is important because besides preserving vascular health, optimizing HDL-C might lead to fewer gouty flares. Therefore, while suppressing serum UA level is an indispensible strategy for reducing gouty flares, optimizing lipid profile with elevation of serum HDL-C level is a potentially important treatment strategy to investigate.
There are a few limitations in this study. First, diagnosis of gout was based on the 1977 ACR criteria for gout, which has long been criticized for its specificities [19] . While the recent European League Against Rheumatism (EULAR) evidence-based recommendation for the diagnosis of gout strongly advocates that demonstration of MSU crystal in SF or tophus aspirates permits a definitive diagnosis of gout [20] , crystal study was not performed in some of our patients because the diagnosis could be made on clinical grounds by experienced rheumatologists. Secondly, the serum HDL-C level may not truly reflect its anti-inflammatory property because HDL-C can functionally be pro-inflammatory or anti-inflammatory [30] [31] [32] . Until further clinico-laboratory studies can characterize the inflammation-related properties of HDL-C in patients with different stages of gout, HDL-C in patients with gout cannot be assumed to be solely antiinflammatory. Thirdly, although the frequency of gouty attack was not statistically associated with the adjusted mean serum UA level in our multiple linear regression model, the high mean serum UA level of our cohort (507.4 AE 15 mmol/l) still confounded the possible association between low serum HDL level and gouty flares from the clinical perspective. As a result of these limitations, the results of the current study should therefore be interpreted with caution.
In summary, we found that a low fasting serum HDL-C level was predictive of more frequent gouty flares in patients with gout. The inflammation-related properties of HDL-C in gout need to be further characterized in order to explore the precise role of HDL-C in gout.
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Rheumatology key messages
Low serum HDL-C predicts gouty flares in gout patients even after adjustment for potential confounders. Like RA, HDL-C may possess anti-inflammatory properties but experiments are required to confirm this. It is tempting to explore, by controlled trials, whether lowering serum HDL-C reduces gouty flares. 
